Carlsmed (NASDAQ:CARL) Stock Price Target Raised at BTIG Research

Carlsmed (NASDAQ:CARL) had its price objective upped by BTIG Research from $24.00 to $26.00 in a report published on Wednesday, MarketBeat.com reports. The brokerage currently has a buy rating on the stock.

A number of other analysts have also commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Carlsmed in a research note on Wednesday, November 4th. Needham & Company LLC upped their price objective on shares of Carlsmed from $17.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday. Wall Street Zen raised shares of Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Truist Financial raised their price objective on shares of Carlsmed from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $22.00.

Carlsmed Trading Up 26.4%

Shares of Carlsmed stock opened at $18.60 on Wednesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 8.66 and a current ratio of 8.84. Carlsmed has a 52 week low of $8.50 and a 52 week high of $19.15. The stock has a 50 day moving average price of $14.91 and a two-hundred day moving average price of $12.54. The stock has a market capitalization of $507.78 million, a PE ratio of -12.57 and a beta of 1.97.

Carlsmed (NASDAQ:CARL) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.08. Carlsmed had a negative return on equity of 40.55% and a negative net margin of 55.82%. The firm had revenue of $21.55 million during the quarter. As a group, equities analysts anticipate that Carlsmed will post -1.50 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CARL. Deutsche Bank AG purchased a new position in shares of Carlsmed in the 2nd quarter worth approximately $106,000. Bank of America Corp DE bought a new stake in Carlsmed during the second quarter worth $108,000. Alpine Woods Capital Investors LLC purchased a new position in Carlsmed in the second quarter worth $161,000. Bank of New York Mellon Corp purchased a new position in Carlsmed in the second quarter worth $181,000. Finally, Zevenbergen Capital Investments LLC grew its stake in Carlsmed by 50.4% in the 3rd quarter. Zevenbergen Capital Investments LLC now owns 17,900 shares of the company’s stock valued at $252,000 after purchasing an additional 6,000 shares during the period.

Key Carlsmed News

Investors following CARL have been watching these news items:

• Positive Sentiment: Carlsmed reported Q3 revenue of $21.6 million, up 65% year over year, and a loss of $0.34 per share—narrower than analysts’ expected $0.42 loss. The company also raised its 2026 revenue forecast to $78 million–$80 million. Carlsmed Q3 results and guidance
• Positive Sentiment: Several firms raised their targets while maintaining Buy ratings: BTIG lifted its target to $26 from $24, Truist to $23 from $20, and Needham to $22 from $17. The revisions signal improved analyst expectations following the quarterly report. Analysts raise Carlsmed forecasts
• Negative Sentiment: Despite beating the quarterly loss estimate, Carlsmed remains unprofitable, reporting a loss for the quarter.

Carlsmed Company Profile

Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. Its technology uses patient-specific planning and implant design to help surgeons plan spinal-fusion procedures. The company’s products include aprevo®, a line of patient-specific interbody implants made using 3D printing. Carlsmed’s platform is designed to use a patient’s imaging and surgical plan to tailor implant geometry and support alignment goals. Founded in 2018 and based in Carlsbad, California, Carlsmed serves the U.S. market.